Sheeba Irshad

3.1k total citations
47 papers, 654 citations indexed

About

Sheeba Irshad is a scholar working on Oncology, Immunology and Infectious Diseases. According to data from OpenAlex, Sheeba Irshad has authored 47 papers receiving a total of 654 indexed citations (citations by other indexed papers that have themselves been cited), including 28 papers in Oncology, 8 papers in Immunology and 7 papers in Infectious Diseases. Recurrent topics in Sheeba Irshad's work include Immunotherapy and Immune Responses (6 papers), SARS-CoV-2 and COVID-19 Research (5 papers) and COVID-19 Clinical Research Studies (5 papers). Sheeba Irshad is often cited by papers focused on Immunotherapy and Immune Responses (6 papers), SARS-CoV-2 and COVID-19 Research (5 papers) and COVID-19 Clinical Research Studies (5 papers). Sheeba Irshad collaborates with scholars based in United Kingdom, United States and Australia. Sheeba Irshad's co-authors include Andrew Tutt, Anita Grigoriadis, Johnathan Watkins, Peter Ellis, Tony Ng, Nick Maisey, Fabian Flores‐Borja, Mieke Van Hemelrijck, Alan Ashworth and Evanthia T. Roussos Torres and has published in prestigious journals such as Journal of Biological Chemistry, Journal of Clinical Oncology and Cancer Research.

In The Last Decade

Sheeba Irshad

39 papers receiving 644 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Sheeba Irshad United Kingdom 15 353 254 134 99 70 47 654
Simona Scalone Italy 16 410 1.2× 207 0.8× 144 1.1× 91 0.9× 109 1.6× 55 784
Ofer Margalit Israel 15 382 1.1× 330 1.3× 209 1.6× 67 0.7× 127 1.8× 52 824
Sharon Wu United States 13 247 0.7× 274 1.1× 113 0.8× 56 0.6× 61 0.9× 68 604
Yao Xie China 13 276 0.8× 308 1.2× 124 0.9× 181 1.8× 103 1.5× 43 822
Susanne A. Gatz United Kingdom 16 267 0.8× 416 1.6× 88 0.7× 150 1.5× 187 2.7× 35 887
Takeshi Yokoo Japan 17 127 0.4× 290 1.1× 122 0.9× 44 0.4× 46 0.7× 74 1.0k
Christoph M. Ahlers United States 14 286 0.8× 232 0.9× 62 0.5× 197 2.0× 70 1.0× 38 690
Nataša Todorović‐Raković Serbia 13 342 1.0× 280 1.1× 117 0.9× 115 1.2× 63 0.9× 43 602
Pooja Advani United States 17 358 1.0× 219 0.9× 102 0.8× 40 0.4× 107 1.5× 67 799

Countries citing papers authored by Sheeba Irshad

Since Specialization
Citations

This map shows the geographic impact of Sheeba Irshad's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Sheeba Irshad with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Sheeba Irshad more than expected).

Fields of papers citing papers by Sheeba Irshad

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Sheeba Irshad. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Sheeba Irshad. The network helps show where Sheeba Irshad may publish in the future.

Co-authorship network of co-authors of Sheeba Irshad

This figure shows the co-authorship network connecting the top 25 collaborators of Sheeba Irshad. A scholar is included among the top collaborators of Sheeba Irshad based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Sheeba Irshad. Sheeba Irshad is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Irshad, Sheeba, et al.. (2025). Risk Factors Associated with Intrauterine Growth Restriction: A Case-Control Study. Pakistan Journal of Health Sciences. 110–114.
2.
Alsaleem, Mansour, Emad A. Rakha, Sheeba Irshad, et al.. (2025). Cardiotoxicity of breast cancer drug treatments. Translational Oncology. 55. 102352–102352. 2 indexed citations
3.
Tonne, Jason M., Jill Thompson, Alex Chen, et al.. (2025). T cell exhaustion in poorly immunogenic HCC is partially rescued by checkpoint blockade but suppressed by oncolytic virotherapy. Molecular Therapy. 33(12). 6178–6194.
4.
Paget, James, Janice Ward, David Mansfield, et al.. (2024). CXCL12-Targeted Immunomodulatory Gene Therapy Reduces Radiation-Induced Fibrosis in Healthy Tissues. Molecular Cancer Therapeutics. 24(3). 431–443.
5.
Maussion, Charles, Anca Mera, Cheryl Gillett, et al.. (2024). Abstract PO2-07-05: Deep learning model for automated quantification of HER2 expression in invasive breast cancers from immunohistochemical whole slide images. Cancer Research. 84(9_Supplement). PO2–7. 1 indexed citations
6.
7.
Flores, Daniel, Joanne Xiu, Irene Kang, et al.. (2024). Evaluation of markers of immunity in different metastatic immune microenvironments suggests more suppression within breast to liver metastases in breast cancer. Breast Cancer Research and Treatment. 206(2). 245–259. 3 indexed citations
8.
Graham, Rosalind, Patrycja Gazińska, Atousa Khiabany, et al.. (2023). Serum-derived extracellular vesicles from breast cancer patients contribute to differential regulation of T-cell-mediated immune-escape mechanisms in breast cancer subtypes. Frontiers in Immunology. 14. 1204224–1204224. 22 indexed citations
9.
McKenzie, Duncan R., Rosalind Graham, Thomas Lechmere, et al.. (2022). Boosting of Waned Humoral and Cellular Responses to SARS-CoV-2 Variants of Concern Among Patients with Cancer. Cancer Research Communications. 2(11). 1449–1461. 1 indexed citations
10.
Kakkassery, Helen, et al.. (2022). Immunogenicity of SARS-CoV-2 vaccines in patients with cancer. Trends in Molecular Medicine. 28(12). 1082–1099. 14 indexed citations
11.
Ting, Jonathan Y., Charlotte Moss, Beth Russell, et al.. (2021). COVID-19 Vaccine Safety in Cancer Patients: A Single Centre Experience. Cancers. 13(14). 3573–3573. 37 indexed citations
12.
Irwin, Gareth, Finian Bannon, Charlotte E. Coles, et al.. (2021). The NeST (Neoadjuvant systemic therapy in breast cancer) study: National Practice Questionnaire of United Kingdom multi-disciplinary decision making. BMC Cancer. 21(1). 90–90. 10 indexed citations
13.
Goode, E., Evanthia T. Roussos Torres, & Sheeba Irshad. (2021). Lymph Node Immune Profiles as Predictive Biomarkers for Immune Checkpoint Inhibitor Response. Frontiers in Molecular Biosciences. 8. 674558–674558. 16 indexed citations
14.
Goode, E., Danielle Crawley, Charlotte Moss, et al.. (2020). 243P UK experience of the management of pregnancy associated breast cancer: A national retrospective review of practice. Annals of Oncology. 31. S337–S337.
15.
16.
Irshad, Sheeba, Fabian Flores‐Borja, Rachel Evans, et al.. (2013). Use of Live In-Vivo Lymphatic Imaging Techniques to Study the Effects of Immune Cell Interactions in a Syngeneic Mouse Model of Breast Cancer. Annals of Oncology. 24. iii40–iii40. 1 indexed citations
17.
Irshad, Sheeba, Alan Ashworth, & Andrew Tutt. (2011). Therapeutic potential of PARP inhibitors for metastatic breast cancer. Expert Review of Anticancer Therapy. 11(8). 1243–1251. 18 indexed citations
18.
Irshad, Sheeba, Emma McLean, Sheila Rankin, et al.. (2010). Unilateral Diffuse Idiopathic Pulmonary Neuroendocrine Cell Hyperplasia and Multiple Carcinoids Treated with Surgical Resection. Journal of Thoracic Oncology. 5(6). 921–923. 13 indexed citations
19.
Irshad, Sheeba, et al.. (2009). Isolation of ORCTL3 in a novel genetic screen for tumor-specific apoptosis inducers. Cell Death and Differentiation. 16(6). 890–898. 11 indexed citations
20.
Budhram‐Mahadeo, Vishwanie, Sheeba Irshad, Samantha Bowen, et al.. (2007). Proliferation-associated Brn-3b transcription factor can activate cyclin D1 expression in neuroblastoma and breast cancer cells. Oncogene. 27(1). 145–154. 17 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Simona Scalone Breakdown of academic impact, for papers by Ofer Margalit Breakdown of academic impact, for papers by Sharon Wu Breakdown of academic impact, for papers by Yao Xie Breakdown of academic impact, for papers by Susanne A. Gatz Breakdown of academic impact, for papers by Takeshi Yokoo Breakdown of academic impact, for papers by Christoph M. Ahlers Breakdown of academic impact, for papers by Nataša Todorović‐Raković Breakdown of academic impact, for papers by Pooja Advani
Rankless by CCL
2026